The clinical study of correlation between cholesterol-lowering therapy and the progression of atherosclerosis in type 2 diabetes mellitus

The clinical study of correlation between cholesterol-lowering therapy and the progression of atherosclerosis in type 2 diabetes mellitus - The clinical study of correlation between cholesterol-lowering therapy and the progression of atherosclerosis in type 2 diabetes mellitus

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015925

Enrollment

200

Registered

2014-12-12

Start date

2014-10-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic disease in type 2 diabetes mellitus

Interventions

&lt

intensive therapy group &gt

Based on guidline, Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012, with the goal of lowering LDL-C to less than 80 mg/dl. &lt

standard therapy group &gt

Based on guidline, JAS Guidelines 2012, with the goal of lowering LDL-C to less than 120 mg/dl.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 Diabetes Mellitus patients whose LDL-C more than 120 mg/dL at the time of the clinical study start

Exclusion criteria

Exclusion criteria: 1.The patients with cerebrovascular disease that developed recently, within 12 weeks. 2.The patients whose fasting triglyceride level>400 mg/dl 3.The patients who have histry of coronary heart disease 4.The patients with liver disfunction 5.The patients with renal disfunction, serum creatinine level is mere than 2 times of the facilities standard. 6.The patients with uncontroled respiratory failure, heart failure and arrhythmia etc. 7.The patients with Familial hypercholesterolemia. 8.The patients with alcoholicsm or medicinal intoxication. 9.The patients who are pregnant, lactating and may be pregnant. 10.The patients who doctors judge as unfitness.

Design outcomes

Primary

Measure	Time frame
1.the progression of intima-media thickness 2.the progression of pulse wave velocity	—

Countries

Japan

Contacts

Public ContactTakeshi Matsumura

Kumamoto University Hospital Metabolism and Endocrinology

takeshim@gpo.kumamoto-u.ac.jp096-373-5169

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026